Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.

@article{Gibbons2008PhaseIA,
  title={Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.},
  author={Joseph Gibbons and Merrill J. Egorin and Ramesh K. Ramanathan and Pingfu Fu and Daniel L. Mulkerin and Stephen I. Shibata and Chris H M Takimoto and Sridhar Mani and Patricia Lorusso and Jean L Grem and Anna C Pavlick and H. P. Lenz and Susan M Flick and Sherrie Reynolds and Theodore F. Lagattuta and Robert A Parise and Yanfeng Wang and Anthony J. Murgo and S Percy Ivy and Scot C. Remick},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 4},
  pages={570-6}
}
PURPOSE This study was undertaken to determine the safety, dose-limiting toxicities (DLT), maximum-tolerated dose (MTD), and pharmacokinetics of imatinib in cancer patients with renal impairment and to develop dosing guidelines for imatinib in such patients. PATIENTS AND METHODS Sixty adult patients with advanced solid tumors and varying renal function (normal, creatinine clearance [CrCL] >or= 60 mL/min; mild dysfunction, CrCL 40 to 59 mL/min; moderate dysfunction, CrCL 20 to 39 mL/min; and… CONTINUE READING